Emapalumab Prevence toxických látek spojených s CAR-T buňkami
Zkouška fáze 2 s emapalumabem pro prevenci toxicit spojených s buňkami CAR-T
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
The research study involves the following study interventions:
- Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
- Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
- Emapalumab
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.
A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.
The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.
This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.
Once study treatment is completed, the participants will be followed for up to 24 months.
It is expected that about 28 people will take part in this research study.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Matthew Frigault, MD
- Telefonní číslo: (617) 643-6175
- E-mail: MFRIGAULT@partners.org
Studijní místa
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Nábor
- Massachusetts General Hospital
-
Vrchní vyšetřovatel:
- Matthew Frigault, MD
-
Kontakt:
- Matthew Frigault, MD
- Telefonní číslo: 617-643-6175
- E-mail: MFRIGAULT@partners.org
-
Boston, Massachusetts, Spojené státy, 02215
- Zatím nenabíráme
- Dana-Farber Cancer Institute
-
Kontakt:
- Caron Jacobson, MD
- Telefonní číslo: (617)-632-5847
- E-mail: Caron_Jacobson@DFCI.HARVARD.EDU
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
-
At least 1 measurable lesion per Lugano at time of screening.
-
Age 18 or older
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Adequate renal, hepatic, pulmonary and cardiac function defined as:
- ANC ≥1000/uL
- Platelet count ≥50,000/uL
- Absolute lymphocyte count ≥100/uL
- Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
- Serum ALT/AST ≤2.5 per institutional ULN
- Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
- Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
- Baseline oxygen saturation >92% on room air.
-
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.
-
Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.
-
History of allogeneic stem cell transplantation.
-
Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.
-
Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.
- Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
-
No evidence of active CNS disease regardless of prior CNS history.
-
History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.
-
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
-
History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.
-
Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
-
History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.
-
Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T
-
In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
-
History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.
-
Receipt of a BCG vaccine within 12 weeks prior to Screening.
-
Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.
-
Participants who are receiving any other investigational agents for this condition.
-
Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Cohort 1a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
Ostatní jména:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
Experimentální: Cohort 1b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
Ostatní jména:
Alkylating agent Purine antagonist antimetabolite Autologous treatment Corticosteroid |
|
Experimentální: Cohort 2a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
Ostatní jména:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
Experimentální: Cohort 2b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
Ostatní jména:
Alkylating agent Purine antagonist antimetabolite Corticosteroid Autologous treatment |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of grade 2+ CRS per ASTCT
Časové okno: Day -1 to 24 months post treatment
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment. |
Day -1 to 24 months post treatment
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Rate and severity of ICANS as per ASTCT
Časové okno: 30 days
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion. |
30 days
|
|
Objective response rate (ORR)
Časové okno: Day -1 to 24 months post treatment
|
The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders. |
Day -1 to 24 months post treatment
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Duration of response (DOR)
Časové okno: From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing. |
From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Progression-free Survival (PFS)
Časové okno: From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date. |
From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Overall survival (OS)
Časové okno: From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date. |
From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Matthew Frigault, MD, Massachusetts General Hospital
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary
- Onemocnění imunitního systému
- Novotvary podle histologického typu
- Lymfatická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Lymfom, B-buňka
- Lymfom
- Hemická a lymfatická onemocnění
- Lymfom, velký B-buňka, difuzní
- Lymfom, Non-Hodgkin
- Lymfom, folikulární
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Organické chemikálie
- Uhlovodíky
- Polycyklické sloučeniny
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Těhotenství
- Těhotenství
- Steroidy
- Sloučeniny roztaveného kruhu
- Steroidy, fluorované
- Fosforamidové hořčice
- Sloučeniny hořčice dusíku
- Hořčičné sloučeniny
- Uhlovodíky, halogenované
- Fosforamidy
- Organofosforové sloučeniny
- Těhotenství
- Dexamethason
- Cyklofosfamid
- Monoklonální protilátky
- Fludarabin fosfát
- Axicabtagene ciloleucel
- Emapalumab
Další identifikační čísla studie
Další identifikační čísla studie
- 24-317
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Časový rámec sdílení IPD
Data can be shared no earlier than 1 year following the date of publication
Kritéria přístupu pro sdílení IPD
Contact the Partners Innovations team at http://www.partners.org/innovation
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .